TITLE

Boceprevir Capsules (Victrelisâ„¢)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
June 2011
SOURCE
Internal Medicine Alert;6/15/2011, Vol. 33 Issue 11, p84
SOURCE TYPE
Periodical
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the boceprevir capsule Victrelis, a protease inhibitor for the treatment of chronic hepatitis C (HCV) infections, from Merck & Co. Inc.
ACCESSION #
61774987

 

Related Articles

  • For the Treatment of Hepatitis C Virus, the Majority of Surveyed U.S. Physicians Who Prescribe Vertex's Incivek More Often Than Merck/Roche's Victrelis Perceive Incivek as Offering a Short, Simple and Highly Efficacious Treatment Option.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article reports on a survey conducted by Decision Resources Group Co. on the U.S. physicians, who prefer to prescribe Vertex Inc.'s protease inhibitor, Incivek over Merck and Co. Inc. protease inhibitor, Victrelis to treat hepatitis C virus. The physicians found that Incivek offers short and...

  • Merck's Hepatitis C Drug Gets FDA Approval. Serebrov, Mari // BioWorld Today;5/16/2011, Vol. 22 Issue 94, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) for Victrellis Friday, a drug developed by Merck & Co. Inc., as a treatment for chronic hepatitis C.

  • Untitled.  // BioWorld Today;4/24/2013, Vol. 24 Issue 78, p7 

    The article reports that Merck & Co. Inc. of Whitehouse Station, New Jersey has announced interim data from a Phase II, multi center, randomized dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172 for the treatment of chronic HCV genotype 1 infection.

  • US physicians eagerly await approval of new HCV drugs.  // PharmacoEconomics & Outcomes News;11/13/2010, Issue 616, p11 

    The article reports that physicians are awaiting for the marketing approval for Vertex's telaprevir and Merck's boceprevir for hepatitis C virus (HCV) infection in the U.S.

  • Merck's HCV combo only partly succeeds. McCaffrey, Kevin // Medical Marketing & Media;Jan2015, Vol. 50 Issue 1, p13 

    The article reports on the interim results of the Hepatitis C Virus (HCV) combination therapy developed by pharmaceutical company Merck.

  • VICTRELIS.  // MPR - Residents' Edition;Fall/Winter2011, Vol. 20 Issue 2, pA:7 

    The article offers brief clinical and pharmacological information on Victrelis, a hepatitis c virus protease inhibitor with boceprevir for treatment of chronic hepatitis C genotype 1 infection from Merck & Co. Inc.

  • Vertex versus Goliaths in hepatitis C drug duel.  // Medical Marketing & Media;Jul2011, Vol. 46 Issue 7, p10 

    The article reports on the success of Vertex Pharmaceuticals Inc. in producing its Incivek (telaprevir), a hepatitis C drug, to the market competing with the Hepatitis C Virus (HCV) drugs of Roche Pharmaceuticals and Merck & Co. Inc.

  • Merck dealt HCV setback; access fight continues. McCaffrey, Kevin // Medical Marketing & Media;Mar2015, Vol. 50 Issue 3, p10 

    The article reports that the U.S. Food and Drug Administration (FDA) has cancelled the Breakthrough Therapy designation for the company Merck & Co. Inc.'s hepatitis C combo drug grazoprevir/elbasvir.

  • Ethical drug updates.  // Australian Journal of Pharmacy;Jan/Feb2017, Vol. 98, p12 

    The article evaluates several drugs, including Xolair to treat allergic asthma, from Novartis, Nucala for asthma treatment, from GlaxoSmithKline, and Zepatier for chronic hepatitis C, from Merck & Co.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics